Please find attached the Quarterly Results along with the Limited Review Report for the quarter ended September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemiesynth (Vapi) Ltd reported Q2 FY26 revenue from operations of ₹687.15 lakhs, up about 36% YoY from ₹505.18 lakhs in Q2 FY25. For H1 FY26, revenue grew roughly 30% YoY to ₹1,084.61 lakhs (vs ₹832.22 lakhs in H1 FY25). Despite top-line growth, the company remained in the red with a Q2 standalone loss of ₹43.95 lakhs versus a profit of ₹25.09 lakhs in Q2 FY25, though the loss narrowed sequentially from ₹76.87 lakhs in Q1 FY26. Operating cash flow stayed healthy at ₹210.54 lakhs for the period. Total equity slipped to ₹1,008.48 lakhs (from ₹1,098.06 lakhs at March 2025) due to accumulated losses, while total borrowings stand at roughly ₹1,521 lakhs (long-term ₹927.53 lakhs + short-term ₹593.42 lakhs). The statutory auditor issued a clean limited review report with no qualifications.
Strong revenue growth is encouraging, but the company continues to post losses and its debt is roughly 1.5x equity — short-term investors should watch for sustained improvement in profitability before considering this stock. The narrowing sequential loss and positive operating cash flow are mildly positive signs for patient shareholders.